ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Dynamic monitoring of serum CEA and CA19-9 predicts the prognosis of postoperative stage II colon cancer

Wang, Ren; Xu, Benjie; Sun, Mingming; Pang, Xiangyi; Wang, Xin; Zhu, Jiahao; Lian, Jie*; Lu, Haibo*哈尔滨医科大学
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY2023-12DOI: 10.1016/j.ejso.2023.107138
5阅读
引用收藏
分享

摘要

Background: We sought to investigate the prognostic significance of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) dynamics for stage II colon cancer patients undergoing radical resection.Methods: This study retrospectively analyzed 1517 stage II colon cancer patients admitted to the Harbin Medical University Cancer Hospital from January 2011 to December 2016. To observe the relationship between tumor markers dynamic monitoring and survival, we calculated cut-off values for Delta CEA and Delta CA19-9. Group according to the cut-off values and compare the differences in survival between subgroups.Results: Preoperative CA199 (HR = 3.122), postoperative CEA (HR = 2.941) and histological type (HR = 2.855) were independent prognostic factors in multivariate Cox proportional hazards models. The 5-year overall survival (OS) in the patients with normal preoperative CEA and CA19-9 was significantly better than the patients with elevated preoperative CEA or CA19-9 and the patients with elevated preoperative CEA and CA19-9 (92.6 % vs. 87.6 % vs. 81.0 %, P < 0.05). 469 patients with normal pre- and post-operative CEA had the highest 5-year OS (93.5 %, P < 0.05). Among the 177 patients with elevated pre- and post-operative CEA, the 5-year OS rate was only 81.8 % (P < 0.05). The cut-off values for Delta CEA and Delta CA19-9 in stage II colon cancer patients with elevated preoperative tumor markers were 2.625 ng/ml and 7.835 U/ml, respectively. The Kaplan-Meier curves showed that Delta CEA >= 2.625 ng/ml and Delta CA19-9 >= 7.835 U/mL were associated with better outcome (87.8 % vs. 79.6 %, P < 0.05; 85.8 % vs. 79.1 %, P > 0.05). At the same time, we found that adjuvant chemotherapy significantly improved 5-year OS in patients with elevated preoperative CEA or CA19-9 (91.0 % vs. 80.9 % and 89.6 % vs. 80.2 %, P < 0.05).Conclusions: Persistent postoperative elevation of CEA/CA19-9 is associated with a poor prognosis. CEA and CA19-9 may be high-risk factors for postoperative adjuvant therapy in stage II colon cancer patients. For stage II colon cancer patients with elevated preoperative CEA, patients with Delta CEA<2.625 ng/ml have poor survival and can improve prognosis by receiving adjuvant therapy.

学科与关键词

关键词
CEACA19-9Colon cancerTumor markersDynamic monitoringOverall survival
相关
加载中…
  • Early Postoperative Serum Carcinoembryonic Antigen Is a Stronger Independent Prognostic Factor for Stage II Colorectal Cancer Patients Than T4 Stage and Preoperative CEA
    Fenqi, Du; Yupeng, Liu; Qiuju, Zhang; Chao, Yuan; Wenjie, Song; Tianyi, Xia; Junnan, Guo; Weinan, Xue; Xiufeng, Jiang; Junge, Bai; Chenyang, Jia; Hua, Xi; Yien, Li; Xuefeng, Bai; Yanlong, LiuFrontiers in Oncology, 2022, 11: 758509.被引 8
  • Adjuvant chemotherapy benefits on patients with elevated carcinoembryonic antigen in stage IIA colon cancer: a SEER-based analysis
    Zhou, Huabin; Wang, Songsheng; Cai, Zhai; Qiu, Enming; Chen, Qianyun; Rao, Xi; Han, Shuai; Li, Zhou*INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2022, 37(12): 2481-2489.
  • Real-world survival of colon cancer after radical surgery: A single-institutional retrospective analysis
    Pang, Xiangyi; Xu, Benjie; Lian, Jie; Wang, Ren; Wang, Xin; Shao, Jiayue; Tang, Shuli; Lu, Haibo*Frontiers in Oncology, 2022, 12: 914076.被引 4
查看全部 →

发表信息

论文状态
公开发表
期刊
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY
发表日期
2023-12
卷期
第 49 卷, 第 12 期
页码
107138
DOI
10.1016/j.ejso.2023.107138
语言
ENGLISH
成果收录
SCIE
资助标注
National Natural Science Foundation of China [U20A20376, 61972116]; Beijing Award Foundation [YXJL-2020-0818-0478]; Wu Jieping Medical Foundation [320.6750.2020-19-20]; Heilongjiang Province Postdoctoral Funding Project [LBH-Z21189]; Harbin Medical University Innovative Science Research Funded Project [31041220028]; China Post-doctoral Science Foundation [2022MD713747]

作者

  • W

    Wang, Ren (第一作者)

    harbin med univ

  • X

    Xu, Benjie

    harbin med univ

查看全部 8 位作者收起作者
  • S

    Sun, Mingming

    qiqihar med univ

  • P

    Pang, Xiangyi

    harbin med univ

  • W

    Wang, Xin

    harbin med univ

  • Z

    Zhu, Jiahao

    harbin med univ

  • L

    Lian, Jie (通讯)

    harbin med univ

  • L

    Lu, Haibo (通讯)

    harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417